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Endovascular grafts offer the potential to dra-
matically alter treatment of patients with an abdom-
inal aortic aneurysm (AAA) by significantly influenc-
ing the risk and morbidity rate of perioperative and
late complications, the duration of recuperation, and
the use of medical resources. This, in turn, is likely
to influence recommendations for treatment and
indications for operation.
However, the overall impact of these changes
will depend on the number of patients ultimately
able to undergo endovascular graft (EVG) place-
ment, which will be determined by the patient’s
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Objective: To determine the percentage of elective abdominal aortic aneurysms (AAAs)/aor-
toiliac aneurysms that currently can be repaired with endovascular grafts (EVGs), the rea-
sons for rejection of EVGs, and the future role of EVG in the treatment of AAA.
Methods: From January 1997 to May 1998, patients at three hospitals (a university hos-
pital, a university-affiliated teaching hospital, and a Veterans Administration hospital
with university faculty and residents) were evaluated for EVGs as part of a national clin-
ical trial with grafts manufactured by Endovascular Technologies (EVT, Menlo Park,
Calif). All patients at two hospitals and patients treated by the participating surgeons at
the third hospital were screened for EVG. Patients with AAAs that were ruptured, symp-
tomatic, or involved renal or mesenteric arteries and patients who declined treatment
were excluded from the study. Evaluation included clinical examination, computed
tomography scan, and selective arteriography. The decision to proceed with EVG was
made by the vascular surgeon, with input and concurrence of medical personnel from a
company with extensive experience in endograft repair. The main outcome measures
were the determination of the percentage of elective AAAs currently being treated with
an EVG and the reasons for exclusion of patients from EVG placement.
Results: A total of 162 patients underwent elective treatment of an AAA, 22 (14%) with an
EVG (14 bifurcated, eight tube) and 140 (86%) with traditional resection. Indications for
not proceeding with an EVG included insufficient proximal cuff in 29 patients (21%), dis-
tal common iliac aneurysm or insufficient distal iliac neck in 29 patients (21%), proximal
neck too large for an EVG in 24 patients (17%), symptomatic iliac stenosis in 23 patients
(16%), iliac stenosis precluding introducer passage in 17 patients (12%), patient preference
in 11 patients (8%), and calcification, kink, or extensive thrombus involving the proximal
neck precluding safe graft attachment in seven patients (5%). Of the 22 patients treated
with an EVG, three were converted to open resection, because of iliac stenosis in two
patients and premature stent deployment in one patient (initial technical success rate, 86%).
Conclusion: Based on currently available technology, 80% of patients were not candidates for
an EVG because of proximal calcification, short aortic or distal cuff, coexisting distal iliac
aneurysm, and stenotic iliac disease. Even with the use of adjunctive procedures, most
patients still require open repair. Significant changes in design will be necessary to apply
these devices to most patients with an AAA. (J Vasc Surg 1999;30:68-75.)
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symptoms, clinical presentation, anatomical con-
straints, physician recommendations, patient prefer-
ence, and third-party reimbursement. This study
reviewed the collective influence of these variables to
better determine the number of patients with an
infrarenal AAA currently able to undergo EVG
placement with grafts from a single manufacturer.
METHODS AND MATERIAL
Patient selection and evaluation for endovas-
cular graft. From January 1997 through May
1998, all patients referred to the authors with an
intact infrarenal AAA were evaluated for possible
EVG placement. The three institutions included a
university hospital, a university-affiliated teaching
hospital, and a Veterans Administration hospital.
These hospitals were participating in a national clin-
ical trial evaluating the endovascular repair of AAA
with a tube or bifurcated EVG manufactured by
Endovascular Technologies (EVT, Menlo Park,
Calif). At two institutions, all patients with an intact
AAA who did not meet the preestablished exclusion
criteria were examined. At the third institution,
patients treated by physicians not participating in the
clinical trial or patients not meeting the preestab-
lished criteria were not included. The studies were
approved by the institutional review board at each
hospital. Criteria used to exclude patients from con-
sideration for an EVG are listed in Table I. Some
patients did not undergo EVG placement because of
personal preference or insurance requirements. 
During this period, 162 patients met eligibility cri-
teria and were evaluated for EVG placement, and
these patients form the basis for this report.
Aneurysm evaluation included clinical evaluation,
computed tomography (CT) scan of the abdomen
and pelvis with 3 to 5 mm sequential images or spiral
CT scan, and selective arteriography. The decision to
proceed with EVG placement was made after evalua-
tion of these studies by the vascular surgeon and med-
ical personnel from a company with extensive experi-
ence with endograft repair of AAA. These medical
personnel specifically reviewed the imaging studies
and provided recommendations for treatment. The
final decision to place the graft rested with the attend-
ing vascular surgeon.
Arteriography was routinely obtained during the
initial period of the study and provided important
information about the patency and contribution of
the inferior mesenteric artery to colonic perfusion,
the angulation of the proximal aortic neck, and the
tortuosity of the aorta and iliac arteries.1 Later, it
became apparent that intraoperative arteriography,
in conjunction with contrast spiral CT with multi-
planar reconstructions, was a means of providing
this information. Indications for preprocedure arte-
riography subsequently included suspected renal or
mesenteric artery involvement, significant iliac
artery aneurysms or ectasia, concomitant aortoiliac
or infrainguinal occlusive disease, or concern regard-
ing the suitability of the iliac and femoral arteries for
device placement. In patients undergoing preproce-
dure arteriography, CT and angiographic findings
were both considered in deciding on graft place-
ment, with the CT scan findings usually given pref-
erence in rare cases of discrepancy. Intraoperative
arteriography findings did not significantly change
clinical management. Magnetic resonance angiogra-
phy, duplex scan, or abdominal ultrasound scanning
were occasionally used as a means of providing addi-
tional anatomic information.
Anatomic criteria. Several anatomic criteria were
required for placement of an EVG. The infrarenal
proximal aneurysm neck had to be less than 26 mm in
diameter to accommodate the largest available grafts
and at least 15 mm long to allow for proximal stent
attachment without compromising the renal orifices.
The proximal aortic neck could not be significantly
calcified or kinked in such a way that it would interfere
with secure stent attachment. No formal criteria was
used to determine an acceptable level of angulation or
extent of calcification; rather, the decision was made
based on the judgement of the vascular surgeon and
medical reviewers trained to predict device success.
For individuals undergoing tube graft placement,
the minimal distal aortic cuff length was 12 mm, to
allow for inferior stent attachment. Patients treated
with a bifurcated graft required 20 mm of non-
aneurysmal distal common iliac artery to permit stent
attachment and seal without compromising hypogas-
Table I. Exclusion criteria for patients with
abdominal aortic aneurysms undergoing evaluation
for endovascular grafts 
Ruptured AAA
Symptomatic AAA
Renal artery stenosis requiring surgical repair
Symptomatic mesenteric vascular disease
Accessory renal arteries requiring preservation
Presence of active infection
Life expectancy less than 2 years 
Connective tissue disorder causing the AAA
Noniatrogenic bleeding diathesis
Patients declining repair of AAA
Patients unable to undergo requisite evaluations
AAA, Abdominal aortic aneurysm.
tric artery perfusion. The minimum common femoral
and external iliac artery diameter was 7.7 mm, to
accommodate a 23 French introducer, and at least one
iliofemoral system had to be patent and without sig-
nificant occlusive disease or tortuosity to allow passage
of the introducer and catheter.
Operative technique. The operative approach
and technique for graft insertion was developed by
EVT and has been previously described by Moore
and Rutherford in their review of the initial EVT
trial.2 The approach was modified when necessary,
because of difficulties with graft insertion, position-
ing, or orientation.
Adjunctive procedures were occasionally used to
facilitate device insertion and passage. Extensive
mobilization of the common femoral and external
iliac artery, with transection of the deep epigastric
and deep inferior circumflex iliac branches, assisted
in straightening of the artery to minimize problems
with tortuosity or angulation. Division of the
inguinal ligament occasionally facilitated access to
the external iliac artery to further reduce tortuosity
or kinking. Transluminal iliac angioplasty, either
with rigid coaxial or balloon dilatation, helped to
ensure passage of the device through moderately
stenotic iliac arteries. Retroperitoneal operative
exposure of the common iliac or external iliac artery
was not used on any patients in this report.
Patients were treated with either a tube (aor-
toaortic) or bifurcated (aortobiiliac) graft. During
the course of this study, an aortoiliac unilateral graft,
in conjunction with a femorofemoral bypass graft,
was available for patients who were otherwise eligible
for EVG placement but who had only a unilateral
suitable distal common iliac artery attachment site.
When necessary, this technique was subsequently
used on three patients at one of the three hospitals.
However, two of the three institutions did not use
this approach, because of concern that the long-term
patency of a femorofemoral bypass graft was less than
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the patency of aortic reconstruction. Selection crite-
ria of patients for EVG placement, however, did not
change during the course of this review.
RESULTS 
During this period, 162 patients (114 men, 48
women) who required elective repair of an infrarenal
AAA were evaluated for an EVG in accordance with
the approved protocol. Twenty-two patients (14%)
were treated with an EVG (14 bifurcated, eight tube),
and 140 patients (86%) were treated with traditional
resection. Conventional treatment in the 140 patients
included tube graft in 79 patients, aortobiiliac in 43
patients, aortobifemoral in 17 patients, and aorta to
left common iliac and right common femoral in one
patient. Three patients underwent a concomitant
femoral endarterectomy. Overall, approximately 270
AAAs were repaired at the three institutions during
the course of this review.
The 140 patients were not suitable for endovas-
cular repair because of insufficient proximal aortic
neck length in 29 patients (21%), distal common
iliac artery aneurysm or insufficient distal neck pre-
cluding common iliac (CI) artery attachment in 29
patients (21%), proximal neck too wide for current-
ly available devices in 24 patients (17%), sympto-
matic iliac artery occlusive disease in 23 patients
(16%), iliac stenosis precluding introducer passage in
17 patients (12%), patient preference or denial of
insurance payment in 11 patients (8%), and calcified
or extremely kinked proximal neck precluding safe
graft attachment in seven patients (5%; Table II).
In all patients, the nonaneurysmal infrarenal
aorta suitable for proximal stent attachment ranged
in length from 8 to 40 mm (mean, 19.7 mm). For
the 29 patients excluded because of insufficient
length, the neck was less than 15 mm in all patients
(mean, 12.0 mm). The size of the proximal aorta
ranged from 16 to 28 mm (mean, 21.5 mm), but
was 26 mm or greater in the 24 patients excluded
because the diameter was larger than available grafts
(mean, 27.1 mm). Seven patients (5%) had a proxi-
mal aortic neck that was thought to be too calcified
or kinked to allow for safe stent attachment.
Twenty-nine patients (21%) had a CI artery
aneurysm extending to within 10 mm of the iliac
bifurcation. None of these patients had sufficient
nonaneurysmal distal CI to allow for an EVG without
compromising the orifice of the hypogastric artery.
The narrowest diameter of either iliac system
ranged from 6.0 to 12.0, with a mean of 7.7 mm.
Seventeen patients (12%) without occlusive symp-
toms had iliac arteries too small for introducer and
Table II. Contraindication to endovascular graft
placement for 140 patients
Number of 
Primary contraindication patients (%)
Proximal neck length 29 (21%)
Insufficient distal neck 29 (21%)
Proximal neck diameter 24 (17%)
Symptomatic iliac occlusive disease 23 (16%)
Iliac stenosis precluding introducer passage 17 (12%)
Patient preference/insurance denial 11 (8%)
Calcified/kinked proximal neck 7 (5%)
catheter placement. These patients did not have a
patent iliac system with a diameter of at least 8 cm
throughout its length (mean, 6.1 mm) and were
therefore not candidates for EVG placement.
Traditional resection in these patients included tube
graft reconstruction in 14 patients and aortobiiliac
bypass grafting in three patients. 
Twenty-three patients had claudication in addi-
tion to the AAA. Open resection included aorto-
bifemoral bypass grafting in 16 patients, aortobiiliac
graft in five patients, aortoiliofemoral bypass grafting
in one patient, and aortoaortic graft in one patient.
Eleven additional patients (7%) could potentially
have been treated with an EVG based on clinical pre-
sentation and CT scan and arteriographic findings.
However, they elected to undergo traditional resec-
tion, either because of concern about the durability
or safety of EVGs, denial of insurance coverage, or to
avoid the 2- to 3-week delay inherent in graft con-
struction and arrangements for supervised insertion.
Overall, only 15% of patients were treated with an
EVG. However, 11 additional patients met the
anatomic and clinical requirements and could have
undergone transfemoral endovascular grafting. These
patients decided to undergo conventional repair
because of personal preference or insurance require-
ments. Including these 11 patients, 33 of the 162
patients (20%) could have potentially been treated
with a tube or bifurcated EVG. An additional 29
patients could have undergone unilateral aortoiliac
grafting with femorofemoral bypass, so 62 patients
(38%) were potential candidates for some form of
endovascular graft manufactured by EVT.
Endovascular repair. Of the 22 patients treated
with an EVG, three were converted to traditional
repair. One patient required conversion because of
premature stent deployment during an otherwise
uncomplicated procedure. Two patients required
conversion because of inability to pass the introducer
through the iliac arteries, despite attempts at rigid and
balloon dilation. CT scan and arteriography findings
in these two patients suggested endovascular repair
may have been possible. Four patients, successfully
treated with an EVG, underwent iliac artery angio-
plasty with balloon dilatation at the time of endovas-
cular repair to allow for graft placement because of
iliac stenosis initially precluding device insertion.
DISCUSSION
Overall applicability. Although the incidence
of perioperative complications after endovascular
grafting for AAA has been reported to range from
10% to 50%,3-5 and the long-term results of the pro-
cedure remain unknown, there have been increasing
efforts to apply EVGs to more patients with
infrarenal AAAs. This has been prompted primarily
by a recognition of the advantages EVGs offer over
traditional resection. These include a reduction in
blood loss, decreased duration of aortic cross-clamp-
ing and cardiac stress, and reduced length and cost
of hospitalization.1,2,6-9 In addition, there have been
no reported cases of aortoenteric fistula or anasto-
motic false aneurysm, and the prevalence of intraab-
dominal adhesions and small bowel obstruction has
been significantly reduced.8
Consequently, several studies that attempt to
determine the percentage of patients with infrarenal
AAAs who are candidates for treatment with an
EVG have been undertaken.1,10-13 These reviews,
however, have usually been from a single institution
and have been limited to a small number of patients.
Patients with concomitant iliofemoral occlusive dis-
ease or patients preferring traditional resection have
generally been excluded. Few studies have reported
on the actual applicability of EVGs to an entire
cohort of patients with infrarenal AAAs. This study
was undertaken to determine not only the anatomic
suitability of EVG, but also the current percentage
of patients with AAAs who are actually benefiting
from the procedure in a national controlled clinical
trial with the EVT device. We found that only 15%
of patients with an AAA were ultimately acceptable
candidates for EVGs.
Several different EVGs are currently used in clini-
cal trials, and many institutions are placing cus-
tomized “homemade” EVGs that have not been
approved for general use.8 Most of these grafts share
many anatomic requirements, including an infrarenal
neck of at least 10 to 15 mm, a distal aortic or iliac
neck of similar length, and a suitable iliofemoral sys-
tem of at least 7 to 8 mm to allow for device insertion.
Thus, although our results reflect the requirements
for one specific graft, they are likely to predict results
that can be obtained with other EVGs.1,4,5,13-19
However, these results cannot necessarily be extrapo-
lated to all other EVGs.
A review of recent studies reveals wide variation
in the percentage of patients with an infrarenal AAA
who are potentially treatable with currently available
EVGs. Estimates range from 10% to 80%, despite
generally similar requirements for graft insertion.
Studies reporting higher eligibility rates have gener-
ally relied on significant use of aortoiliac bypass
grafts combined with a femorofemoral bypass graft,
modular grafts, or specially constructed grafts with
large proximal necks.1,13,15,18,20-24
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Larger AAAs are more likely to have anatomic
characteristics complicating or precluding endovas-
cular repair. These include a higher incidence of
associated iliac aneurysms, more aortic and iliac tor-
tuosity, loss of the distal aortic cuff that precludes
aortoaortic reconstruction, more angulation and
kinking, and increased thrombus at the site of prox-
imal or distal attachment.12,18,25 Therefore, reviews
involving repair of small (4 to 5 cm) AAAs general-
ly have found a higher percentage of patients poten-
tially treated with EVGs and a lower incidence of
complications than studies on patients with larger
aneurysms.5,18 One study predicted 71% of patients
with an AAA less than 60 mm in maximum diame-
ter could be treated with an EVG, in contrast with
37% for aneurysms larger than 60 mm.18
Moore and Rutherford,2 reporting on the initial
phase I Food and Drug Administration-approved
clinical trial, found only 13% of patients could be
treated with a tube graft, but many of these patients
could have been treated with a bifurcated prosthesis.
Several recent reports have estimated 50% to 60% of
patients are candidates for an EVG.5,11,13-15,18,26,27
Proximal aortic attachment. In our experience
and the experience of other authors, the length of the
proximal neck was the most common contraindica-
tion to EVG placement.11,12,28,29 We found 29
patients (21%) had a neck less than 15 mm, which
precluded the use of an EVG. The critical factor in
proximal stent attachment is thought to be preserva-
tion of the renal artery orifices. Some reports have
noted that stents crossing renal ostia have not
impaired renal function.15,25 Most surgeons, howev-
er, remain reluctant to place stents into the renal
ostia, and the late effects of this approach remain
unknown. 
The development of stent grafts with suprarenal
attachment and fenestrations at the level of the renal
arteries to allow for renal perfusion may significant-
ly increase the use of EVGs, because this will allow
EVG placement in some patients with an infrarenal
neck that is too large, too short, kinked, tortuous, or
severely calcified. 
Only grafts 26 mm or smaller were available in
the EVT trial, and 17% of patients in our study were
excluded because the proximal neck was larger than
26 mm. Other studies have found the mean diame-
ter of the nonaneurysmal aorta ranges from 21 to 25
cm, similar to the 22 mm in our experience.11,18,28
Grafts larger than 26 mm have been constructed and
successfully placed,1 but their deployment may
require larger introducers and, therefore, a larger
iliofemoral system.
Proximal aortic neck angulation, kinking, or tor-
tuosity are difficult to overcome, and most reports
have found an EVG cannot be safely placed in these
circumstances. Some studies have routinely excluded
patients with angulation of the proximal neck
greater than 75 degrees,1 and other studies have
reported a higher incidence of endoleak or stent
migration. Aneurysm rupture has been reported
after the placement of a graft into an irregular aortic
neck or significant intraluminal thrombus.28 Other
reviews, however, reported the successful attach-
ment of the proximal graft in three patients with sig-
nificant calcification, and in four patients with aortic
angulation of 80 degrees or less.16 Although we did
not specifically measure the degree of angulation,
severe tortuosity or kinking affected seven patients
in our study, and other reports have noted an inci-
dence as high as 11%.6,15
Iliac artery disease. Graft placement was con-
traindicated because of iliac artery occlusive disease
in 40 patients in our study. Twenty-three of these
patients had lower-extremity ischemic symptoms,
and 16 required an aortofemoral bypass grafting
procedure for treatment of both the AAA and asso-
ciated occlusive disease. The other 17 patients did
not have an iliac artery large enough to accommo-
date the introducer system. The diameter of the iliac
arteries in our studies was similar to that in the
reports of others, and no currently available devices
can be placed through iliac arteries less than 8
mm.13 In one study, 7% of patients found to be suit-
able for EVGs based on preoperative imaging stud-
ies required conversion to open repair because of
iliac artery disease, and four other patients required
an additional endovascular procedure because of
symptomatic iliac stenosis with lower-extremity
ischemia.1 Direct retroperitoneal exposure of the
iliac arteries has increased applicability, but has been
associated with a significantly increased length of
hospitalization, operating time, and blood loss.4
In our study, common iliac artery aneurysms
precluded EVGs in 29 patients (21%), and other
reports have found a similar incidence of iliac
aneurysmal disease.11-13,15,18 Iliac tortuosity, even
without aneurysmal degeneration, may preclude
device insertion. Additional stents are frequently
required to exclude an iliac aneurysm, adding to the
length and potential technical problems of the pro-
cedure.15
Unilateral aortoiliac grafts and modular devices
may increase the applicability of the procedure to
patients with aneurysmal iliac arteries.1,13,15,30-32 An
additional 29 patients (18%) in our experience could
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potentially have been treated with a unilateral aorta-
to-external-iliac bypass graft and a femorofemoral
graft. However, this approach was not used during
the course of this study because of our concern that
the patency of the crossover graft is significantly less
than the patency of bilateral anatomic reconstruc-
tion. At one of the institutions participating in our
study, however, three of these grafts have subse-
quently been successfully placed and remained
patent without complications. 
However, others have used this approach fre-
quently, and, in some studies, this was the most
common form of endovascular repair.1,13 Follow-up
of this approach is limited, but it is possible that the
patency of femorofemoral grafts placed in individu-
als without significant occlusive disease may, in fact,
be significantly better than the patency of bypass
grafts placed in patients with ischemic symptoms,
and this would significantly increase the applicability
of EVG.1,13,29 This approach may jeopardize colonic
perfusion, and colonic ischemia has been reported
after EVG placement with unilateral or bilateral
hypogastric ligation.28,33
Patient preference. Eleven patients in our study
were offered EVGs but preferred traditional resection,
in most cases because of concerns about the durability
of endovascular repair or the complications and uncer-
tainty of endoleaks. Other patients chose standard
repair because insurance would not cover EVG place-
ment. In all reports, some patients have declined
EVGs,1 but as experience with EVGs increases and
concerns about late complications subside, the pro-
portion of patients desiring EVGs is likely to increase.
Attempts to increase applicability. Because of
the anatomic limitations facing all EVGs, several cur-
rent attempts are being made to modify the graft
and delivery system to improve applicability.
Problems with access or iliac artery stenosis affect a
significant number of patients, 40% in this study.
These difficulties have prompted attempts to devel-
op smaller deployment catheters. A 16F delivery sys-
tem has been developed and tested in an animal
model, and grafts as large as 24 mm in diameter have
been inserted through an 18F sheath.10 However,
no actual clinical experience with the device has been
reported. If the introducer could be inserted
through a 6 or 7 mm iliac artery, an additional 17
patients (10%) in our study could have been treated
with an EVG. However, even if this introducer were
clinically available, only grafts 24 cm or smaller
could be placed through this system, and 26 patients
(19%) in our study required a graft with a diameter
larger than 24 mm.
Iliac angioplasty enabled four additional patients
in our study to be treated with an EVG, but most of
the other patients with stenotic iliac arteries could
not be improved sufficiently with either rigid coaxi-
al or balloon dilatation to allow for device insertion.
Although it was not successfully used in our series,
direct iliac exposure with attachment of a Dacron
cuff to the CI was found in other studies to provide
access for an EVG.1
General considerations. The safety and clinical
success of the procedure need to be firmly estab-
lished so insurance carriers will cover the procedure;
the requisite imaging modalities need to be avail-
able, and support personnel need to be trained.
Combined with device modifications, these factors
are likely to increase the proportion of patients with
an AAA who can be treated with an EVG.
CONCLUSION
Based on currently available technology, as many
as 80% of patients are not candidates for an EVG
because of proximal calcification, short aortic or dis-
tal cuff, coexisting distal iliac aneurysm, and stenotic
iliac disease. Even with the use of adjunctive proce-
dures, including iliac angioplasty and open retroperi-
toneal iliac artery exposure to facilitate EVG place-
ment, most patients still require open repair.
However, the development of grafts with fenestra-
tions to allow suprarenal attachment while maintain-
ing renal perfusion, the advent of smaller grafts and
introducers, and the increased use of aortoiliac
reconstruction may significantly increase the number
of patients who will benefit from an EVG. 
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Dr Victor Bernhard (Menlo Park, Calif). The manage-
ment of infrarenal abdominal aortic aneurysm (AAA) by
means of endograft exclusion appears to be both feasible and
safe in the short term; however, long-term follow-up will be
required to determine the ultimate usefulness of this form of
therapy. One of the important questions about this less-inva-
sive approach to AAA repair is what proportion of patients
can be treated with this less-invasive technique. Dr Treiman
and his associates have attempted to answer this question by
reviewing the imaging studies and clinical characteristics of
patients referred for AAA repair to three hospitals associated
with two major academic centers. One hundred sixty-two
patients with intact aneurysms were evaluated for endograft
therapy with devices provided by Guidant-EVT in a Food
and Drug Administration protocol. Of these, 22 patients, or
13.6%, were considered appropriate for endograft deploy-
ment, and the remaining 140 were treated with standard
open surgery. One hundred twenty-nine patients were
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rejected, based on anatomic criteria; however, 11 patients
(6.8%) were excluded for reasons that were unrelated to
anatomic or physiologic inclusion criteria and may well have
been included in the category of acceptable candidates.
Therefore, the total number of patients who could have been
considered for endograft therapy was 33 (20.4%).
Candidacy for treatment by endograft deployment is
dependent on these factors: differences in device design
among manufacturers, the anatomic requirements for a
satisfactory deployment, and the accruing experiences of
operating teams and device manufacturers in patient selec-
tion and the techniques of implant insertion.
To conclude that “endovascular grafts are contraindi-
cated in most patients,” all currently available designs
would have to be considered before a given patient’s can-
didacy could be accepted or rejected. Because the authors’
study was confined to endografts provided by only one
manufacturer, this study cannot truly support the authors’
primary hypothesis.
Endografts from all manufacturers are designed to be
applicable in a variety of circumstances. These include tube
grafts for patients who have an adequate length of distal aor-
tic neck for secure deployment of the distal attachment
mechanism and bifurcation grafts for patients who don’t
have a satisfactory distal aorta but do have adequate attach-
ment sites in their iliac arteries. A unilateral aortoiliac con-
figuration complimented by a femorofemoral bypass graft is
available for those patients with only one iliac artery that is
satisfactory for endograft attachment because of a variety of
anatomic factors that prevent contralateral deployment. The
authors indicated reluctance to use aortoiliac devices in those
patients who could not be treated with tube and bifurcation
endografts. This may have significantly limited the applica-
tion of endovascular therapy in their patient population.
Femoral artery access for insertion of the deployment
catheter is preferred. However, successful access through
the distal common iliac artery with a limited retroperi-
toneal incision has been reported without a significant
increase in morbidity. The frequency of endograft repair in
this study may have been further reduced because the
authors did not use this approach.
The three hospitals involved in this investigation are
acknowledged referral centers for complex vascular prob-
lems. As a consequence, the authors may have been the
recipients of a distorted segment of the aneurysm popula-
tion that did not reflect the average anatomic characteris-
tics of AAA patients. This factor may have reduced the
number of acceptable candidates. However, these institu-
tions were also known to be among the few where endo-
graft therapy for AAA was available, and this confounding
variable may have had a reverse effect on the patient popu-
lation being studied.
I have six questions for Dr Treiman.
Were all the patients referred to the three hospitals
with elective abdominal aortic aneurysms included in this
study? This issue was not clearly defined in the manuscript.
Were any of the patients rejected because of Food and
Drug Administration protocol restrictions that would not
have prevented their acceptance for endograft therapy based
on purely anatomic and clinical criteria?
Although you were reluctant to use the unilateral aor-
toiliac/femorofemoral bypass grafting technique, were all
patients fully evaluated for the potential application of all
three devices before they were rejected as unsuitable can-
didates?
Were patients with inadequate access because of iliac
stenosis considered as potential candidates when a
retroperitoneal approach to the common iliac was anatom-
ically feasible?
What proportion of the patients in your study would
have been acceptable candidates for endograft repair,
rather than standard surgery, if inclusion was based entire-
ly on anatomic grounds?
Would you speculate on the effect of referral patterns
as possibly significant variables in this study?
I would like to commend the authors on an excellent
effort to determine the applicability of endograft proce-
dures for the treatment of abdominal aortic aneurysm.
Dr Gerald S. Treiman. All the patients referred to the
authors who met the outlined criteria were examined. At
one institution, patients who were treated by surgeons not
involved in the trial were not examined. At two institu-
tions, all authors were participating in the clinical trial.
None of the 162 patients in this study were candidates
for endovascular grafts but were excluded because of Food
and Drug Administration protocol restrictions. However,
patients clearly not able to undergo preoperative and
required postoperative examinations because of their dis-
tance from the examination site or travel restrictions were
not examined with computed tomography for possible
endovascular grafts.
All patients were not evaluated for unilateral aortoiliac
endovascular grafts preoperatively. Evaluation for this
reconstruction was only made on subsequent review of
imaging studies as part of this study.
Patients who had iliac stenosis were not routinely eval-
uated for retroperitoneal exposure of the common iliac
artery. This was considered in some patients, but was not
used during the period of this study.
If inclusion was based entirely on anatomic grounds, and
unilateral aortoiliac bypass grafting was used, 38% of patients
could potentially have been treated with an endovascular
graft. Additional patients could possibly be treated if
retroperitoneal exposure was more aggressively used.
Because all the institutions are referral centers, many
patients are specifically referred to these hospitals because of
large or extensive aneurysms, and these aneurysms are less
likely to be treatable with an endovascular graft. This would
tend to reduce the apparent applicability of the procedure.
However, because these institutions were the only centers in
their respective geographic areas offering endovascular
grafts, some patients were referred because of aneurysms
thought to be suitable for endovascular grafts because of
their configurations. This might increase the apparent applic-
ability. The combined effect of these competing influences
cannot be conclusively determined.
